Denali opts in for F-star's Fcabs

Neurodegenerative company Denali Therapeutics Inc. (NASDAQ:DNLI) has exercised an option to acquire F-star Gamma Ltd., an asset-centric subsidiary of F-star Biotechnology Ltd. (Cambridge, U.K.). The deal gives Denali rights to Fcabs against blood-brain barrier (BBB) receptor proteins.

Fcabs are Fc domains that can bind to antigens. They can be used to create bispecific mAbs that can cross the BBB and bind to targets within the CNS. The Fcabs were generated using F-star’s Modular Antibody Technology...